Technology is not new. Biotechnology is not new; it’s new-ish. Yet when the two come together to look at how they can transform medicine, its creation, delivery, and access, well, that is new and can be extraordinary. Extraordinary enough that the FDA established the Emerging Technology Team (ETT) in the Office of Pharmaceutical Quality (OPQ) of the Center for Drug Evaluation and Research (CDER) in 2015.
Sau Lee, PhD, who chairs the team, explains the ETT’s intentions and outlook in our cover story, “Just Getting Started: 3D Printing and Bioprinting in Pharmaceutical Manufacturing.” In that story, author Scott Fotheringham, PhD, looks at 3D printing and bioprinting. He pursues still other technological advances in his feature “A Good Fit: The Marriage of Pharma and Tech Yields Benefits for Patients,” discussing several pharma/tech alliances and their ambitions.
Our chapter profile highlights ambition, too. Mike McGrath spoke with the Great Lakes Chapter President Deborah Geyman about its recent financial struggles and how she sees brighter days ahead—did you know Great Lakes serves more than 800 members scattered across the six states surrounding Lake Erie and Lake Michigan? On this same topic of ambition, tenacity, and diligence, Mary Foss offers thoughtful advice to students entering the industry for the first time, and our regular columnist David Smith reveals the best way to “ace” a telephone interview.
Our technical authors look at patient safety from novel angles: applying QRM to reduce HVAC costs (Appleby, et al.), the benefits of ozone technology in water pharmaceutical systems (Cohen and Johnson), how to minimize and control microbiological contamination in water systems (Sandle), the reliability of sterility assurance tests (Stering), and a method for demonstrating content uniformity (Stepanic and Saeed).
All in all, we have a little bit of something for everyone in this issue, and I hope you enjoy it. To view these articles and more, check out the July – August 2017 issue of Pharmaceutical Engineering® magazine.
Stability sampling and testing are key to ensuring that products maintain safety, identity, strength, purity, and quality throughout their claimed shelf life. It is also a regulatory requirement per ICH Q5. However, storing product samples in different environmental conditions, testing those samples for three to five years (or more) after initial manufacture, and properly analyzing and...
ISPE hosted more than 450 attendees in person and virtually for the 2024 ISPE Aseptic Conference in Vienna, Austria. Keynotes and education sessions provided a comprehensive overview of key topics and trends...
Biopharmaceutical facility design is a critical aspect of the industry. Overall cost pressures in the global health system, regional requirements to deploy manufacturing rather than centralize manufacturing in one location, technology enhancements in cell biology and format, flexibility to accommodate multi-product campaigns with different production schedules, and speed-to-market are among...